Hancock Whitney Corporation (NYSE:HWC) will release earnings results for the third quarter, after the closing bell on Tuesday, Oct. 14.Analysts expect the Gulfport, Mississippi-based company to report quarterly earnings at $1.43 per share, up from $1.33 per share in the year-ago period. Hancock Whitney projects quarterly revenue of $391.24 million, compared to $370.35 million a year earlier, according to data from Benzinga Pro.On July 15, Hancock Whitney posted better-than-expected results for the second qu ...

Company Overview - Amgen Inc. (AMGN) is a leading global biotechnology company with a market cap of $158.6 billion, headquartered in Thousand Oaks, California, focusing on innovative human therapeutics for serious illnesses, particularly in oncology, nephrology, cardiovascular disease, and inflammation [1] Earnings Expectations - Amgen is expected to release its fiscal Q3 2025 earnings results on November 4, with analysts predicting a profit of $5.01 per share, which represents a 10.2% decrease from $5.58 per share in the same quarter last year [2] - For fiscal 2025, analysts forecast an EPS of $21.10, indicating a 6.4% increase from $19.84 in fiscal 2024 [3] Stock Performance - Over the past 52 weeks, Amgen's stock has declined by 8.4%, underperforming the S&P 500 Index, which gained 16.3%, and the Health Care Select Sector SPDR Fund, which saw a 6% dip [4] Recent Developments - On October 1, Amgen's shares surged by 6.4% following the announcement of a $650 million investment to expand its U.S. biologics manufacturing facility in Juncos, which is expected to create nearly 750 new jobs, emphasizing the company's commitment to U.S. biomanufacturing and global supply chain strength [5] Analyst Ratings - The consensus rating for AMGN stock is "Moderate Buy," with 33 analysts covering the stock, including 12 "Strong Buys," 2 "Moderate Buys," 16 "Holds," 1 "Moderate Sell," and 2 "Strong Sells." The average analyst price target for AMGN is $315.26, suggesting a potential upside of 6.7% from current levels [6]

Core Insights - Meta Platforms, Inc. (META) is valued at a market cap of $1.8 trillion and operates major social media platforms including Facebook, Instagram, WhatsApp, Messenger, and Threads [1] - The company is set to announce its fiscal Q3 earnings for 2025 on October 29, 2023 [1] Financial Performance - Analysts expect META to report a profit of $6.74 per share for Q3 2025, an increase of 11.8% from $6.03 per share in the same quarter last year [2] - For fiscal 2025, the expected profit is $28.14 per share, representing a 17.9% increase from $23.86 per share in fiscal 2024 [3] - EPS is projected to grow 5.6% year-over-year to $29.71 in fiscal 2026 [3] Stock Performance - META's stock has increased by 21.1% over the past 52 weeks, outperforming the S&P 500 Index's return of 17.4% but lagging behind the Communication Services Select Sector SPDR Fund's 27.8% increase [4] - Following better-than-expected Q2 results, META's shares rose by 11.3% in the subsequent trading session [5] Analyst Ratings - Wall Street analysts have a "Strong Buy" rating for META, with 47 out of 57 analysts recommending "Strong Buy" [6] - The mean price target for META is $872, indicating a potential upside of 21.5% from current levels [6]

Core Viewpoint - Invesco Ltd. is set to announce its fiscal third-quarter earnings for 2025, with analysts projecting a profit increase compared to the previous year [1][2]. Financial Performance - Analysts expect Invesco to report earnings per share (EPS) of $0.46, reflecting a 4.6% increase from $0.44 in the same quarter last year [2]. - For the full fiscal year, EPS is anticipated to be $1.82, which is a 6.4% rise from $1.71 in fiscal 2024, and projected to increase by 30.2% to $2.37 in fiscal 2026 [3]. Stock Performance - Invesco's stock has outperformed the S&P 500 Index, gaining 38.3% over the past 52 weeks compared to the index's 17.4% increase [4]. - The stock also surpassed the Financial Select Sector SPDR Fund's 18% gains during the same period [4]. Recent Earnings Report - Following the Q2 earnings report on July 22, Invesco shares rose by 5.2%, with net revenue increasing by 1.7% year-over-year to $1.1 billion, attributed to higher investment management fees [5]. - Assets under management (AUM) reached a record $2 trillion, marking a 16.6% increase from the previous year due to strong net inflows [5]. - However, adjusted EPS fell by 16.3% to $0.36, missing estimates by 12.2% [5]. Analyst Ratings - The consensus opinion on Invesco stock is cautious, with a "Hold" rating from 16 analysts, of which three recommend a "Strong Buy" and 13 suggest a "Hold" [6]. - The average analyst price target for Invesco is $24.34, indicating a potential upside of 1.4% from current levels [6].

Citigroup Inc. (NYSE:C) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.Analysts expect the New York-based company to report quarterly earnings at $1.76 per share, up from $1.51 per share in the year-ago period. Citigroup projects quarterly revenue of $21.12 billion, compared to $20.32 billion a year earlier, according to data from Benzinga Pro.On Sept. 24, Citigroup announced $2.75 billion redemption of 5.610% Fixed Rate/Floating Rate Notes due 2026.Shares o ...

Core Insights - PepsiCo is set to announce its Q3 earnings results on October 9th, before market opening [1] - Wall Street anticipates an EPS of $2.26 for the company [1] - Revenue is projected to increase by 2% to $23.84 billion [1] Financial Expectations - Expected EPS: $2.26 [1] - Expected revenue: $23.84 billion, reflecting a 2% increase [1]

Core Insights - Kimberly-Clark Corporation is a multinational company specializing in hygiene and personal care products, with a market capitalization of $39.99 billion and operations in over 175 countries [1] Financial Performance - The company is expected to report a 10.9% year-over-year decline in profit to $1.63 per diluted share for Q3 fiscal 2025 [2] - For the fiscal year 2025, analysts predict an 11% decrease in profit to $6.50 per diluted share compared to the previous year [3] Stock Performance - Kimberly-Clark's stock has underperformed the broader market, losing 13.1% over the past 52 weeks and 6.7% year-to-date, while the S&P 500 Index has gained 17.9% and 14.2% respectively [4] - The company has also underperformed the Consumer Staples Select Sector SPDR Fund (XLP), which has dropped 3.1% over the past 52 weeks [5] Recent Results - In Q2, Kimberly-Clark reported net sales of $4.16 billion, a 1.6% year-over-year decrease, impacted by a 4.4% adverse effect from divestitures and business exits [6] - The adjusted EPS for Q2 was $1.92, down 2% year-over-year but exceeding analyst expectations of $1.68, leading to a 4.8% intraday stock rise on the reporting day [6]

New York-based KKR & Co. Inc. (KKR) is a private equity and real estate investment firm with a market cap of $111.1 billion. The company specializes in acquisitions, leveraged buyouts, management buyouts, credit special situations, growth equity, mature, mezzanine, distressed, turnaround, lower middle market, and middle market investments. It is scheduled to announce its fiscal Q3 earnings for 2025 before the market opens on Friday, Nov. 7. Before this event, analysts expect this private equity giant to r ...

Core Insights - The Procter & Gamble Company (PG) is set to announce its fiscal Q1 earnings for 2026 on October 24, with a market cap of $357 billion and a diverse portfolio of well-known consumer goods brands [1] Financial Performance - Analysts predict PG will report a profit of $1.90 per share for fiscal Q1 2026, a decrease of 1.6% from $1.93 per share in the same quarter last year [2] - For fiscal 2026, PG is expected to achieve a profit of $6.99 per share, reflecting a 2.3% increase from $6.83 per share in fiscal 2025, with further growth anticipated to $7.42 per share in fiscal 2027 [3] Recent Stock Performance - Over the past 52 weeks, PG's stock has declined by 9.2%, underperforming the S&P 500 Index, which returned 17.9%, and the Consumer Staples Select Sector SPDR Fund, which saw a 3.4% decrease [4] - In its Q4 results reported on July 29, PG's net sales rose by 1.7% year-over-year to $20.9 billion, slightly exceeding consensus estimates, while net earnings increased by 15.3% to $3.6 billion [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for PG, with 11 analysts recommending "Strong Buy," 3 suggesting "Moderate Buy," and 11 advising "Hold," indicating a mean price target of $171, which suggests a potential upside of 12.1% from current levels [6]

San Diego, California-based ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders. Valued at a market cap of $41.1 billion, the company is scheduled to announce its fiscal Q1 earnings for 2026 in the near future. Before this event, analysts expect this healthcare company to report a profit of $2.49 per share, up 13.2% from $2.20 per share in the year-ago quarter. The company has a promis ...